IMBRUVICA Drug Patent Profile
✉ Email this page to a colleague
When do Imbruvica patents expire, and when can generic versions of Imbruvica launch?
Imbruvica is a drug marketed by Pharmacyclics Llc and is included in three NDAs. There are forty-one patents protecting this drug and four Paragraph IV challenges.
This drug has three hundred and sixty-four patent family members in forty-three countries.
The generic ingredient in IMBRUVICA is ibrutinib. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ibrutinib profile page.
DrugPatentWatch® Generic Entry Outlook for Imbruvica
Imbruvica was eligible for patent challenges on November 13, 2017.
There have been twelve patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There are six tentative approvals for the generic drug (ibrutinib), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for IMBRUVICA
International Patents: | 364 |
US Patents: | 41 |
Applicants: | 1 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 97 |
Clinical Trials: | 151 |
Patent Applications: | 491 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for IMBRUVICA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for IMBRUVICA |
What excipients (inactive ingredients) are in IMBRUVICA? | IMBRUVICA excipients list |
DailyMed Link: | IMBRUVICA at DailyMed |


Recent Clinical Trials for IMBRUVICA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Peter MacCallum Cancer Centre, Australia | Phase 2 |
Oncternal Therapeutics, Inc | Phase 3 |
Academic and Community Cancer Research United | Phase 2 |
Pharmacology for IMBRUVICA
Drug Class | Kinase Inhibitor |
Mechanism of Action | Protein Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for IMBRUVICA
Paragraph IV (Patent) Challenges for IMBRUVICA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
IMBRUVICA | Capsules | ibrutinib | 70 mg | 205552 | 1 | 2018-12-14 |
IMBRUVICA | Tablets | ibrutinib | 280 mg and 420 mg | 210563 | 1 | 2018-12-14 |
IMBRUVICA | Tablets | ibrutinib | 140 mg and 560 mg | 210563 | 1 | 2018-11-05 |
IMBRUVICA | Capsules | ibrutinib | 140 mg | 205552 | 8 | 2017-11-13 |
US Patents and Regulatory Information for IMBRUVICA
IMBRUVICA is protected by forty-four US patents and twelve FDA Regulatory Exclusivities.
Patents protecting IMBRUVICA
Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods of treating and preventing graft versus host disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of bruton's tyrosine kinase (Btk)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of bruton's tyrosine kinase (BTK)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods of treating and preventing graft versus host disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a brutons tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Inhibitors of bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of bruton'S tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of bruton's tyrosine kinase (Btk)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Crystalline forms of a bruton's tyrosine kinase inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods of treating and preventing graft versus host disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of bruton's tyrosine kinase (BTK)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of bruton's tyrosine kinase (Btk)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Use of inhibitors of bruton'S tyrosine kinase (BTK)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting IMBRUVICA
TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial
FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷ Try a Trial
FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷ Try a Trial
FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷ Try a Trial
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Try a Trial
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Try a Trial
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Try a Trial
INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
Exclusivity Expiration: ⤷ Try a Trial
FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Exclusivity Expiration: ⤷ Try a Trial
TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
Exclusivity Expiration: ⤷ Try a Trial
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Try a Trial
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
EU/EMA Drug Approvals for IMBRUVICA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Janssen-Cilag International NV | Imbruvica | ibrutinib | EMEA/H/C/003791 IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM. |
Authorised | no | no | no | 2014-10-21 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for IMBRUVICA
When does loss-of-exclusivity occur for IMBRUVICA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2844
Estimated Expiration: ⤷ Try a Trial
Patent: 3832
Estimated Expiration: ⤷ Try a Trial
Patent: 8108
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 13271918
Estimated Expiration: ⤷ Try a Trial
Patent: 16226279
Estimated Expiration: ⤷ Try a Trial
Patent: 16250445
Estimated Expiration: ⤷ Try a Trial
Patent: 18211201
Estimated Expiration: ⤷ Try a Trial
Patent: 18211216
Estimated Expiration: ⤷ Try a Trial
Patent: 20239751
Estimated Expiration: ⤷ Try a Trial
Patent: 21240244
Estimated Expiration: ⤷ Try a Trial
Patent: 23200435
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2014030424
Estimated Expiration: ⤷ Try a Trial
Patent: 2017018931
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 75986
Estimated Expiration: ⤷ Try a Trial
Patent: 76695
Estimated Expiration: ⤷ Try a Trial
Patent: 91994
Estimated Expiration: ⤷ Try a Trial
Patent: 15208
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 14003306
Estimated Expiration: ⤷ Try a Trial
Patent: 17000371
Estimated Expiration: ⤷ Try a Trial
Patent: 17003496
Estimated Expiration: ⤷ Try a Trial
China
Patent: 4736178
Estimated Expiration: ⤷ Try a Trial
Patent: 7427498
Estimated Expiration: ⤷ Try a Trial
Patent: 0354132
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 40408
Estimated Expiration: ⤷ Try a Trial
Costa Rica
Patent: 140558
Estimated Expiration: ⤷ Try a Trial
Dominican Republic
Patent: 014000274
Estimated Expiration: ⤷ Try a Trial
Patent: 017000152
Estimated Expiration: ⤷ Try a Trial
Patent: 022000096
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 14033163
Estimated Expiration: ⤷ Try a Trial
Patent: 19015794
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 1492082
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 54859
Estimated Expiration: ⤷ Try a Trial
Patent: 65084
Estimated Expiration: ⤷ Try a Trial
Guatemala
Patent: 1400281
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 08803
Estimated Expiration: ⤷ Try a Trial
Patent: 49015
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 5894
Estimated Expiration: ⤷ Try a Trial
Patent: 3995
Estimated Expiration: ⤷ Try a Trial
Patent: 2367
Estimated Expiration: ⤷ Try a Trial
Patent: 3284
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 36071
Estimated Expiration: ⤷ Try a Trial
Patent: 37086
Estimated Expiration: ⤷ Try a Trial
Patent: 49076
Estimated Expiration: ⤷ Try a Trial
Patent: 15518885
Estimated Expiration: ⤷ Try a Trial
Patent: 18012710
Estimated Expiration: ⤷ Try a Trial
Patent: 18048182
Estimated Expiration: ⤷ Try a Trial
Patent: 18507200
Estimated Expiration: ⤷ Try a Trial
Patent: 19203008
Estimated Expiration: ⤷ Try a Trial
Patent: 20015744
Estimated Expiration: ⤷ Try a Trial
Patent: 21183617
Estimated Expiration: ⤷ Try a Trial
Patent: 21193095
Estimated Expiration: ⤷ Try a Trial
Patent: 22141701
Estimated Expiration: ⤷ Try a Trial
Jordan
Patent: 0200222
Estimated Expiration: ⤷ Try a Trial
Patent: 54
Estimated Expiration: ⤷ Try a Trial
Malaysia
Patent: 7999
Estimated Expiration: ⤷ Try a Trial
Patent: 4911
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 8290
Estimated Expiration: ⤷ Try a Trial
Patent: 14014848
Estimated Expiration: ⤷ Try a Trial
Patent: 17011270
Estimated Expiration: ⤷ Try a Trial
Patent: 21012478
Estimated Expiration: ⤷ Try a Trial
Morocco
Patent: 711
Estimated Expiration: ⤷ Try a Trial
Patent: 643
Estimated Expiration: ⤷ Try a Trial
Patent: 654
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 2548
Estimated Expiration: ⤷ Try a Trial
Patent: 3828
Estimated Expiration: ⤷ Try a Trial
Patent: 1932
Estimated Expiration: ⤷ Try a Trial
Patent: 7725
Estimated Expiration: ⤷ Try a Trial
Peru
Patent: 150174
Estimated Expiration: ⤷ Try a Trial
Patent: 190390
Estimated Expiration: ⤷ Try a Trial
Philippines
Patent: 014502681
Estimated Expiration: ⤷ Try a Trial
Patent: 020500028
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 17133990
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 202101389T
Estimated Expiration: ⤷ Try a Trial
Patent: 202102078V
Estimated Expiration: ⤷ Try a Trial
Patent: 201408067Y
Estimated Expiration: ⤷ Try a Trial
Patent: 201707122Q
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1907661
Estimated Expiration: ⤷ Try a Trial
Patent: 2105174
Estimated Expiration: ⤷ Try a Trial
Patent: 2105175
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 150015021
Estimated Expiration: ⤷ Try a Trial
Patent: 170091785
Estimated Expiration: ⤷ Try a Trial
Patent: 170122220
Estimated Expiration: ⤷ Try a Trial
Patent: 190040370
Estimated Expiration: ⤷ Try a Trial
Patent: 200017549
Estimated Expiration: ⤷ Try a Trial
Patent: 210033067
Estimated Expiration: ⤷ Try a Trial
Patent: 220093389
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 32912
Estimated Expiration: ⤷ Try a Trial
Patent: 53041
Estimated Expiration: ⤷ Try a Trial
Patent: 62963
Estimated Expiration: ⤷ Try a Trial
Patent: 62964
Estimated Expiration: ⤷ Try a Trial
Patent: 33027
Estimated Expiration: ⤷ Try a Trial
Patent: 1402122
Estimated Expiration: ⤷ Try a Trial
Patent: 1636023
Estimated Expiration: ⤷ Try a Trial
Patent: 1811334
Estimated Expiration: ⤷ Try a Trial
Patent: 1902483
Estimated Expiration: ⤷ Try a Trial
Patent: 1906612
Estimated Expiration: ⤷ Try a Trial
Patent: 2211924
Estimated Expiration: ⤷ Try a Trial
Tunisia
Patent: 14000492
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 4421
Estimated Expiration: ⤷ Try a Trial
Uruguay
Patent: 848
Estimated Expiration: ⤷ Try a Trial
Patent: 740
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering IMBRUVICA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2020202752 | The use of inhibitors of Bruton's tyrosine kinase (Btk) | ⤷ Try a Trial |
Israel | 282367 | צורות גבישיות של מעכב ברוטון טירוסין קינאז (Crystalline forms of a bruton's tyrosine kinase inhibitor) | ⤷ Try a Trial |
Australia | 2022202686 | Methods of treating and preventing graft versus host disease | ⤷ Try a Trial |
Mexico | 2016005294 | METODOS PARA TRATAR Y PREVENIR ENFERMEDAD INJERTO CONTRA HUÉSPED. (METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE.) | ⤷ Try a Trial |
Denmark | 2526933 | ⤷ Try a Trial | |
Eurasian Patent Organization | 201000599 | ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ БРУТОНА | ⤷ Try a Trial |
Israel | 223181 | (r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin 1-yl)prop-2-en-1-one for use as a medicament for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for IMBRUVICA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2526934 | CA 2016 00056 | Denmark | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530 |
2526934 | 300844 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 - C(2016)3293 20160530 |
2201840 | C 2015 016 | Romania | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB SAU O SARE FARMACEUTIC ACCEPTABILA A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/14/945; DATE OF NATIONAL AUTHORISATION: 20141021; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/945; DATE OF FIRST AUTHORISATION IN EEA: 20141021 |
2201840 | 15C0029 | France | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023 |
2529621 | CA 2017 00012 | Denmark | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707 |
2201840 | 18/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
2201840 | 122015000027 | Germany | ⤷ Try a Trial | PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |